clinical trial · NCT07357740
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
Novo Nordisk A/S·phase2·not yet recruiting·n = 400
Diabetes Mellitus, Type 2CagriSemaPlacebo CagriSema
brief summary
This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. The study will last for about 38 weeks.
started
Aug 27, 2026
primary completion
Aug 25, 2027
completion
Oct 13, 2027
last updated
Mar 30, 2026
official title
A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol